Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FungiFoam is an over-the-counter topical antifungal foam developed and marketed by Tetra Corporation. Its active ingredient is tolnaftate at a 1% concentration, a well-established antifungal agent. The product features a unique delivery system where oil-soluble tolnaftate is dissolved in natural jojoba oil, which facilitates rapid skin absorption and direct delivery of the medication to infected areas. FungiFoam is indicated for the treatment and prevention of athlete's foot (tinea pedis) and ringworm (tinea corporis), providing relief from symptoms such as itching, scaling, cracking, redness, and burning. It is marketed as a four-in-one product that combines antifungal treatment with anti-pruritic, moisturizing, and exfoliating properties. The product is primarily dispensed through physician offices and is designed for daily use to prevent the recurrence of fungal infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FungiFoam.